Both GlaxoSmithKline and Boehringer Ingelheim say that the EuropeanMedicines Evaluation Agency has approved their respective antihypertensive products, PritorPlus and MicardisPlus (telmisartan plus hydrochlorothiazide). Telmisartan is a subtype 1 angiotensin II receptor antagonist, while HCZ is a diuretic belonging to the thiazides family.
The combination therapy provided by the two companies is intended for certain groups of patients with hypertension who are particularly difficult to control and will be available as a fixed-dose combination of telmisartan (40mg and 80mg) and HCZ (12.5mg).
MicardisPlus will be co-marketed in certain countries by GSK, under the PritorPlus brand name, including European Union member states. GSK currently promotes its Pritor (telmisartan) brand in a number of international and European countries under a co-marketing agreement with Boehringer Ingelheim.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze